Review by : Aldouri M
This is a first case report on using rFVIIa (Novoseven) to treat hemophilia patients with high response inhibitors to factor VIII in Singapore. The patients had bleeding with moderate severity, and it is noticeable that all of them responded very well to few doses and less amount of Novoseven than is usually recommended, due to limited supply and cost of therapy. The authors conclude that rFVIIa was established as frontline therapy for their hemophilia patients with inhibitors.
– M. Aldouri